Due to our extensive coverage of the Keystone Symposia meeting, we will not include any spotlights this week. We will report on the AACR Annual Meeting next week, so our regular digest will be back on April 24th.
There are no spotlights this week
SpotlightDue to our extensive coverage of the Keystone Symposia meeting, we will not include any spotlights this week. We will report on the AACR Annual Meeting next week, so our regular digest will be back on April 24th.
Neoadjuvant nivolumab or nivolumab plus LAG-3 inhibitor relatlimab in resectable esophageal/gastroesophageal junction cancer: a phase Ib trial and ctDNA analyses Spotlight
(1) Kelly RJ (2) Landon BV (3) Zaidi AH (4) Singh D (5) Canzoniero JV (6) Balan A (7) Hales RK (8) Voong KR (9) Battafarano RJ (10) Jobe BA (11) Yang SC (12) Broderick S (13) Ha J (14) Marrone KA (15) Pereira G (16) Rao N (17) Borole A (18) Karaindrou K (19) Belcaid Z (20) White JR (21) Ke S (22) Amjad AI (23) Weksler B (24) Shin EJ (25) Thompson E (26) Smith KN (27) Pardoll DM (28) Hu C (29) Feliciano JL (30) Anagnostou V (31) Lam VK
Kelly, Landon, and Zaidi et al. reported the safety, feasibility, and efficacy of neoadjuvant nivolumab (Arm A) or nivolumab plus relatlimab (Arm B) combined with chemoradiotherapy in patients with resectable stage II/stage III gastroesophageal cancer. The primary endpoint of safety for Arm A was met, but required an amendment to mitigate toxicity in Arm B. The pCR rate was 40% for Arm A and 21.4% for Arm B, and the 2-year OS rates were 82.6% in Arm A and 93.8% in Arm B. Circulating tumor DNA (ctDNA) analysis was predictive of tumor regression, RFS, and OS, outperforming pCR and MPR. Neoantigen-specific T cell responses paralleled ctDNA kinetics.
Contributed by Shishir Pant
(1) Kelly RJ (2) Landon BV (3) Zaidi AH (4) Singh D (5) Canzoniero JV (6) Balan A (7) Hales RK (8) Voong KR (9) Battafarano RJ (10) Jobe BA (11) Yang SC (12) Broderick S (13) Ha J (14) Marrone KA (15) Pereira G (16) Rao N (17) Borole A (18) Karaindrou K (19) Belcaid Z (20) White JR (21) Ke S (22) Amjad AI (23) Weksler B (24) Shin EJ (25) Thompson E (26) Smith KN (27) Pardoll DM (28) Hu C (29) Feliciano JL (30) Anagnostou V (31) Lam VK
Kelly, Landon, and Zaidi et al. reported the safety, feasibility, and efficacy of neoadjuvant nivolumab (Arm A) or nivolumab plus relatlimab (Arm B) combined with chemoradiotherapy in patients with resectable stage II/stage III gastroesophageal cancer. The primary endpoint of safety for Arm A was met, but required an amendment to mitigate toxicity in Arm B. The pCR rate was 40% for Arm A and 21.4% for Arm B, and the 2-year OS rates were 82.6% in Arm A and 93.8% in Arm B. Circulating tumor DNA (ctDNA) analysis was predictive of tumor regression, RFS, and OS, outperforming pCR and MPR. Neoantigen-specific T cell responses paralleled ctDNA kinetics.
Contributed by Shishir Pant
ABSTRACT: Gastroesophageal cancer dynamics and drivers of clinical responses with immune checkpoint inhibitors (ICI) remain poorly understood. Potential synergistic activity of dual programmed cell death protein 1 (PD-1) and lymphocyte-activation gene 3 (LAG-3) inhibition may help improve immunotherapy responses for these tumors. We report a phase Ib trial that evaluated neoadjuvant nivolumab (Arm A, n = 16) or nivolumab-relatlimab (Arm B, n = 16) in combination with chemoradiotherapy in 32 patients with resectable stage II/stage III gastroesophageal cancer together with an in-depth evaluation of pathological, molecular and functional immune responses. Primary endpoint was safety; the secondary endpoint was feasibility; exploratory endpoints included pathological complete (pCR) and major pathological response (MPR), recurrence-free survival (RFS) and overall survival (OS). The study met its primary safety endpoint in Arm A, although Arm B required modification to mitigate toxicity. pCR and MPR rates were 40% and 53.5% for Arm A and 21.4% and 57.1% for Arm B. Most common adverse events were fatigue, nausea, thrombocytopenia and dermatitis. Overall, 2-year RFS and OS rates were 72.5% and 82.6%, respectively. Higher baseline programmed cell death ligand 1 (PD-L1) and LAG-3 expression were associated with deeper pathological responses. Exploratory analyses of circulating tumor DNA (ctDNA) showed that patients with undetectable ctDNA post-ICI induction, preoperatively and postoperatively had a significantly longer RFS and OS; ctDNA clearance was reflective of neoantigen-specific T cell responses. Our findings provide insights into the safety profile of combined PD-1 and LAG-3 blockade in gastroesophageal cancer and highlight the potential of ctDNA analysis to dynamically assess systemic tumor burden during neoadjuvant ICI that may open a therapeutic window for future intervention. ClinicalTrials.gov registration: NCT03044613 .
Author Info: (1) The Charles A. Sammons Cancer Center, Baylor University Medical Center, Dallas, TX, USA. ronan.kelly@bswhealth.org. (2) The Sidney Kimmel Comprehensive Cancer Center, Johns Hop
Author Info: (1) The Charles A. Sammons Cancer Center, Baylor University Medical Center, Dallas, TX, USA. ronan.kelly@bswhealth.org. (2) The Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, MD, USA. (3) Allegheny Health Network Cancer Institute, Allegheny Health Network, Pittsburgh, PA, USA. (4) The Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, MD, USA. The Bloomberg-Kimmel Institute of Cancer Immunotherapy, Johns Hopkins University School of Medicine, Baltimore, MD, USA. (5) The Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, MD, USA. (6) The Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, MD, USA. (7) The Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, MD, USA. Department of Radiation Oncology, Johns Hopkins University School of Medicine, Baltimore, MD, USA. (8) The Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, MD, USA. Department of Radiation Oncology, Johns Hopkins University School of Medicine, Baltimore, MD, USA. (9) Department of Surgery, Johns Hopkins University School of Medicine, Baltimore, MD, USA. (10) Allegheny Health Network Cancer Institute, Allegheny Health Network, Pittsburgh, PA, USA. (11) Department of Surgery, Johns Hopkins University School of Medicine, Baltimore, MD, USA. (12) Department of Surgery, Johns Hopkins University School of Medicine, Baltimore, MD, USA. (13) Department of Surgery, Johns Hopkins University School of Medicine, Baltimore, MD, USA. (14) The Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, MD, USA. The Bloomberg-Kimmel Institute of Cancer Immunotherapy, Johns Hopkins University School of Medicine, Baltimore, MD, USA. (15) The Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, MD, USA. (16) The Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, MD, USA. (17) The Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, MD, USA. (18) The Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, MD, USA. (19) The Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, MD, USA. (20) The Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, MD, USA. (21) The Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, MD, USA. Department of Biostatistics, Bloomberg School of Public Health, Johns Hopkins University, Baltimore, MD, USA. (22) Allegheny Health Network Cancer Institute, Allegheny Health Network, Pittsburgh, PA, USA. (23) Allegheny Health Network Cancer Institute, Allegheny Health Network, Pittsburgh, PA, USA. (24) Department of Gastroenterology & Hepatology, Johns Hopkins University School of Medicine, Baltimore, MD, USA. (25) Department of Pathology, Johns Hopkins University School of Medicine, Baltimore, MD, USA. (26) The Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, MD, USA. The Bloomberg-Kimmel Institute of Cancer Immunotherapy, Johns Hopkins University School of Medicine, Baltimore, MD, USA. (27) The Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, MD, USA. The Bloomberg-Kimmel Institute of Cancer Immunotherapy, Johns Hopkins University School of Medicine, Baltimore, MD, USA. (28) The Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, MD, USA. Department of Biostatistics, Bloomberg School of Public Health, Johns Hopkins University, Baltimore, MD, USA. (29) The Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, MD, USA. (30) The Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, MD, USA. vanagno1@jhmi.edu. The Bloomberg-Kimmel Institute of Cancer Immunotherapy, Johns Hopkins University School of Medicine, Baltimore, MD, USA. vanagno1@jhmi.edu. Lung Cancer Precision Medicine Center of Excellence, Johns Hopkins University School of Medicine, Baltimore, MD, USA. vanagno1@jhmi.edu. (31) The Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, MD, USA. vklam@jhmi.edu.
Citation: Nat Med 2024 Mar 19 Epub03/19/2024
Link to PUBMED: http://www.ncbi.nlm.nih.gov/pubmed/38504015
Targeting refractory/recurrent neuroblastoma and osteosarcoma with anti-CD3_anti-GD2 bispecific antibody armed T cells
(1) Yankelevich M (2) Thakur A (3) Modak S (4) Chu R (5) Taub J (6) Martin A (7) Schalk D (8) Schienshang A (9) Whitaker S (10) Rea K (11) Lee DW (12) Liu Q (13) Shields AF (14) Cheung NV (15) Lum LG
(1) Yankelevich M (2) Thakur A (3) Modak S (4) Chu R (5) Taub J (6) Martin A (7) Schalk D (8) Schienshang A (9) Whitaker S (10) Rea K (11) Lee DW (12) Liu Q (13) Shields AF (14) Cheung NV (15) Lum LG
Author Info: (1) St. Christopher's Hospital for Children, Philadelphia, Pennsylvania, USA yankelevic@gmail.com LGL4F@uvahealth.org. Children's Hospital of Michigan, Detroit, Michigan, USA. (2)
Author Info: (1) St. Christopher's Hospital for Children, Philadelphia, Pennsylvania, USA yankelevic@gmail.com LGL4F@uvahealth.org. Children's Hospital of Michigan, Detroit, Michigan, USA. (2) University of Virginia Cancer Center, Charlottesville, Virginia, USA. (3) Department of Pediatrics, Memorial Sloan Kettering Cancer Center, New York, New York, USA. (4) Children's Hospital of Michigan, Detroit, Michigan, USA. (5) Children's Hospital of Michigan, Detroit, Michigan, USA. (6) Children's Hospital of Michigan, Detroit, Michigan, USA. (7) University of Virginia Cancer Center, Charlottesville, Virginia, USA. (8) University of Virginia Cancer Center, Charlottesville, Virginia, USA. (9) University of Virginia Cancer Center, Charlottesville, Virginia, USA. (10) University of Virginia Cancer Center, Charlottesville, Virginia, USA. (11) University of Virginia Cancer Center, Charlottesville, Virginia, USA. (12) Wistar Institute, Philadelphia, Pennsylvania, USA. (13) Karmanos Cancer Institute, Detroit, Michigan, USA. (14) Department of Pediatrics, Memorial Sloan Kettering Cancer Center, New York, New York, USA. (15) University of Virginia Cancer Center, Charlottesville, Virginia, USA yankelevic@gmail.com LGL4F@uvahealth.org.
Citation: J Immunother Cancer 2024 Mar 21 12: Epub03/21/2024
Link to PUBMED: http://www.ncbi.nlm.nih.gov/pubmed/38519053
CD155 as an emerging target in tumor immunotherapy
(1) Wu JW (2) Liu Y (3) Dai XJ (4) Liu HM (5) Zheng YC (6) Liu HM
(1) Wu JW (2) Liu Y (3) Dai XJ (4) Liu HM (5) Zheng YC (6) Liu HM
Author Info: (1) State Key Laboratory of Esophageal Cancer Prevention & Treatment, Key Laboratory of Advanced Drug Preparation Technologies, Ministry of Education of China, Key Laboratory of He
Author Info: (1) State Key Laboratory of Esophageal Cancer Prevention & Treatment, Key Laboratory of Advanced Drug Preparation Technologies, Ministry of Education of China, Key Laboratory of Henan Province for Drug Quality and Evaluation, XNA Platform, School of Pharmaceutical Sciences, Zhengzhou University, 100 Kexue Avenue, Zhengzhou, Henan 450001, China. (2) Henan Engineering Research Center for Application & Translation of Precision Clinical Pharmacy, Department of Pharmacy, The First Affiliated Hospital of Zhengzhou University, 1 Jianshe East Road, Zhengzhou 450052, China. (3) State Key Laboratory of Esophageal Cancer Prevention & Treatment, Key Laboratory of Advanced Drug Preparation Technologies, Ministry of Education of China, Key Laboratory of Henan Province for Drug Quality and Evaluation, XNA Platform, School of Pharmaceutical Sciences, Zhengzhou University, 100 Kexue Avenue, Zhengzhou, Henan 450001, China. (4) State Key Laboratory of Esophageal Cancer Prevention & Treatment, Key Laboratory of Advanced Drug Preparation Technologies, Ministry of Education of China, Key Laboratory of Henan Province for Drug Quality and Evaluation, XNA Platform, School of Pharmaceutical Sciences, Zhengzhou University, 100 Kexue Avenue, Zhengzhou, Henan 450001, China. (5) State Key Laboratory of Esophageal Cancer Prevention & Treatment, Key Laboratory of Advanced Drug Preparation Technologies, Ministry of Education of China, Key Laboratory of Henan Province for Drug Quality and Evaluation, XNA Platform, School of Pharmaceutical Sciences, Zhengzhou University, 100 Kexue Avenue, Zhengzhou, Henan 450001, China. Electronic address: yichaozheng@zzu.edu.cn. (6) State Key Laboratory of Esophageal Cancer Prevention & Treatment, Key Laboratory of Advanced Drug Preparation Technologies, Ministry of Education of China, Key Laboratory of Henan Province for Drug Quality and Evaluation, XNA Platform, School of Pharmaceutical Sciences, Zhengzhou University, 100 Kexue Avenue, Zhengzhou, Henan 450001, China. Electronic address: liuhuimin@zzu.edu.cn.
Citation: Int Immunopharmacol 2024 Mar 21 131:111896 Epub03/21/2024
Link to PUBMED: http://www.ncbi.nlm.nih.gov/pubmed/38518596
The role of extracellular vesicle immune checkpoints in cancer
(1) Zhang W (2) Ou M (3) Yang P (4) Ning M
(1) Zhang W (2) Ou M (3) Yang P (4) Ning M
Author Info: (1) Department of Laboratory Medicine, Nanjing Drum Tower Hospital, The Affiliated Hospital of Nanjing University Medical School, Nanjing, Jiangsu, China. (2) Department of Laborat
Author Info: (1) Department of Laboratory Medicine, Nanjing Drum Tower Hospital, The Affiliated Hospital of Nanjing University Medical School, Nanjing, Jiangsu, China. (2) Department of Laboratory Medicine, Nanjing Drum Tower Hospital Clinical College of Nanjing Medical University, Nanjing Jiangsu, China. (3) Department of Laboratory Medicine, Nanjing Drum Tower Hospital, The Affiliated Hospital of Nanjing University Medical School, Nanjing, Jiangsu, China. (4) Department of Laboratory Medicine, Nanjing Drum Tower Hospital, The Affiliated Hospital of Nanjing University Medical School, Nanjing, Jiangsu, China.
Citation: Clin Exp Immunol 2024 Mar 22 Epub03/22/2024
Link to PUBMED: http://www.ncbi.nlm.nih.gov/pubmed/38518192
Targeting pediatric cancers via T-cell recognition of the monomorphic MHC class I-related protein MR1
(1) Cornel AM (2) van der Sman L (3) van Dinter JT (4) Arrabito M (5) Dunnebach E (6) van Hoesel M (7) Kluiver TA (8) Lopes AP (9) Dautzenberg NMM (10) Dekker L (11) van Rijn JM (12) van den Beemt DAMH (13) Buhl JL (14) du Chatinier A (15) Barneh F (16) Lu Y (17) Lo Nigro L (18) Krippner-Heidenreich A (19) Sebestyn Z (20) Kuball J (21) Hulleman E (22) Drost J (23) van Heesch S (24) Heidenreich OT (25) Peng WC (26) Nierkens S
(1) Cornel AM (2) van der Sman L (3) van Dinter JT (4) Arrabito M (5) Dunnebach E (6) van Hoesel M (7) Kluiver TA (8) Lopes AP (9) Dautzenberg NMM (10) Dekker L (11) van Rijn JM (12) van den Beemt DAMH (13) Buhl JL (14) du Chatinier A (15) Barneh F (16) Lu Y (17) Lo Nigro L (18) Krippner-Heidenreich A (19) Sebestyn Z (20) Kuball J (21) Hulleman E (22) Drost J (23) van Heesch S (24) Heidenreich OT (25) Peng WC (26) Nierkens S
Author Info: (1) Prinses Maxima Centrum voor Kinderoncologie, Utrecht, The Netherlands. Center for Translational Immunology, UMC Utrecht, Utrecht, The Netherlands. (2) Prinses Maxima Centrum vo
Author Info: (1) Prinses Maxima Centrum voor Kinderoncologie, Utrecht, The Netherlands. Center for Translational Immunology, UMC Utrecht, Utrecht, The Netherlands. (2) Prinses Maxima Centrum voor Kinderoncologie, Utrecht, The Netherlands. Center for Translational Immunology, UMC Utrecht, Utrecht, The Netherlands. (3) Center for Translational Immunology, UMC Utrecht, Utrecht, The Netherlands. (4) Center for Translational Immunology, UMC Utrecht, Utrecht, The Netherlands. Center of Pediatric Hematology & Oncology, University of Catania, Catania, Italy. (5) Prinses Maxima Centrum voor Kinderoncologie, Utrecht, The Netherlands. Center for Translational Immunology, UMC Utrecht, Utrecht, The Netherlands. (6) Prinses Maxima Centrum voor Kinderoncologie, Utrecht, The Netherlands. (7) Prinses Maxima Centrum voor Kinderoncologie, Utrecht, The Netherlands. (8) Prinses Maxima Centrum voor Kinderoncologie, Utrecht, The Netherlands. (9) Center for Translational Immunology, UMC Utrecht, Utrecht, The Netherlands. (10) Center for Translational Immunology, UMC Utrecht, Utrecht, The Netherlands. (11) Center for Translational Immunology, UMC Utrecht, Utrecht, The Netherlands. (12) Prinses Maxima Centrum voor Kinderoncologie, Utrecht, The Netherlands. (13) Center for Translational Immunology, UMC Utrecht, Utrecht, The Netherlands. Oncode Institute, Utrecht, The Netherlands. (14) Center for Translational Immunology, UMC Utrecht, Utrecht, The Netherlands. (15) Center for Translational Immunology, UMC Utrecht, Utrecht, The Netherlands. (16) Center for Translational Immunology, UMC Utrecht, Utrecht, The Netherlands. (17) Center of Pediatric Hematology & Oncology, University of Catania, Catania, Italy. (18) Center for Translational Immunology, UMC Utrecht, Utrecht, The Netherlands. (19) Prinses Maxima Centrum voor Kinderoncologie, Utrecht, The Netherlands. (20) Prinses Maxima Centrum voor Kinderoncologie, Utrecht, The Netherlands. Department of Hematology, UMC Utrecht, Utrecht, The Netherlands. (21) Center for Translational Immunology, UMC Utrecht, Utrecht, The Netherlands. (22) Center for Translational Immunology, UMC Utrecht, Utrecht, The Netherlands. Oncode Institute, Utrecht, The Netherlands. (23) Center for Translational Immunology, UMC Utrecht, Utrecht, The Netherlands. (24) Center for Translational Immunology, UMC Utrecht, Utrecht, The Netherlands. (25) Center for Translational Immunology, UMC Utrecht, Utrecht, The Netherlands. (26) Prinses Maxima Centrum voor Kinderoncologie, Utrecht, The Netherlands S.Nierkens-2@prinsesmaximacentrum.nl. Center for Translational Immunology, UMC Utrecht, Utrecht, The Netherlands.
Citation: J Immunother Cancer 2024 Mar 21 12: Epub03/21/2024
Link to PUBMED: http://www.ncbi.nlm.nih.gov/pubmed/38519054
An IRF2-Expressing Oncolytic Virus Changes the Susceptibility of Tumor Cells to Antitumor T cells and Promotes Tumor Clearance
(1) Shao L (2) Srivastava R (3) Delgoffe GM (4) Thorne SH (5) Sarkar SN
(1) Shao L (2) Srivastava R (3) Delgoffe GM (4) Thorne SH (5) Sarkar SN
Author Info: (1) University of Pittsburgh, Pittsburgh, PA, United States. (2) University of Pittsburgh, Pittsburgh, PA, United States. (3) University of Pittsburgh, Pittsburgh, PA, United State
Author Info: (1) University of Pittsburgh, Pittsburgh, PA, United States. (2) University of Pittsburgh, Pittsburgh, PA, United States. (3) University of Pittsburgh, Pittsburgh, PA, United States. (4) University of Pittsburgh, Pittsburgh, PA, United States. (5) University of Pittsburgh, Pittsburgh, PA, United States.
Citation: Cancer Immunol Res 2024 Mar 22 Epub03/22/2024
Link to PUBMED: http://www.ncbi.nlm.nih.gov/pubmed/38517470
Cryopreserved leukapheresis material can Be transferred from controlled rate freezers to ultracold storage at warmer temperatures without affecting downstream CAR-T cell culture performance and in-vitro functionality
(1) Wei J (2) Chaney K (3) Shim WJ (4) Chen H (5) Leonard G (6) O'Brien S (7) Liu Z (8) Jiang J (9) Ulrey R
(1) Wei J (2) Chaney K (3) Shim WJ (4) Chen H (5) Leonard G (6) O'Brien S (7) Liu Z (8) Jiang J (9) Ulrey R
Author Info: (1) Cell Therapy Technical Operations, R&D Oncology, AstraZeneca, One MedImmune Way, Gaithersburg, MD, USA. (2) Cell Therapy Technical Operations, R&D Oncology, AstraZeneca, One Me
Author Info: (1) Cell Therapy Technical Operations, R&D Oncology, AstraZeneca, One MedImmune Way, Gaithersburg, MD, USA. (2) Cell Therapy Technical Operations, R&D Oncology, AstraZeneca, One MedImmune Way, Gaithersburg, MD, USA. (3) Cell Therapy Technical Operations, R&D Oncology, AstraZeneca, One MedImmune Way, Gaithersburg, MD, USA. (4) Cell Therapy Technical Operations, R&D Oncology, AstraZeneca, One MedImmune Way, Gaithersburg, MD, USA. (5) Cell Therapy Technical Operations, R&D Oncology, AstraZeneca, One MedImmune Way, Gaithersburg, MD, USA. (6) Cell Therapy Technical Operations, R&D Oncology, AstraZeneca, One MedImmune Way, Gaithersburg, MD, USA. (7) Cell Therapy Technical Operations, R&D Oncology, AstraZeneca, One MedImmune Way, Gaithersburg, MD, USA. (8) Cell Therapy Technical Operations, R&D Oncology, AstraZeneca, One MedImmune Way, Gaithersburg, MD, USA. (9) Cell Therapy Technical Operations, R&D Oncology, AstraZeneca, One MedImmune Way, Gaithersburg, MD, USA. Electronic address: robert.ulrey@astrazeneca.com.
Citation: Cryobiology 2024 Mar 19 104889 Epub03/19/2024
Link to PUBMED: http://www.ncbi.nlm.nih.gov/pubmed/38513998
Tags:
Inhibition of IL-25/IL-17RA improves immune-related adverse events of checkpoint inhibitors and reveals antitumor activity
(1) Hu X (2) Bukhari SM (3) Tymm C (4) Adam K (5) Lerrer S (6) Henick BS (7) Winchester RJ (8) Mor A
(1) Hu X (2) Bukhari SM (3) Tymm C (4) Adam K (5) Lerrer S (6) Henick BS (7) Winchester RJ (8) Mor A
Author Info: (1) Center for Translational Immunology, Columbia University Irving Medical Center, New York, New York, USA. (2) Center for Translational Immunology, Columbia University Irving Med
Author Info: (1) Center for Translational Immunology, Columbia University Irving Medical Center, New York, New York, USA. (2) Center for Translational Immunology, Columbia University Irving Medical Center, New York, New York, USA. (3) Center for Translational Immunology, Columbia University Irving Medical Center, New York, New York, USA. (4) Center for Translational Immunology, Columbia University Irving Medical Center, New York, New York, USA. (5) Center for Translational Immunology, Columbia University Irving Medical Center, New York, New York, USA. (6) Herbert Irving Comprehensive Cancer Center, Columbia University Irving Medical Center, New York, New York, USA. (7) Center for Translational Immunology, Columbia University Irving Medical Center, New York, New York, USA. Division of Rheumatology, Columbia University Irving Medical Center, New York, New York, USA. (8) Center for Translational Immunology, Columbia University Irving Medical Center, New York, New York, USA am5121@cumc.columbia.edu. Division of Rheumatology, Columbia University Irving Medical Center, New York, New York, USA.
Citation: J Immunother Cancer 2024 Mar 21 12: Epub03/21/2024
Link to PUBMED: http://www.ncbi.nlm.nih.gov/pubmed/38519059
Design and Evaluation of Synthetic Delivery Formulations for Peptide-Based Cancer Vaccines
(1) Song K (2) Pun SH
(1) Song K (2) Pun SH
Author Info: (1) Department of Bioengineering, University of Washington, USA. (2) Department of Bioengineering, University of Washington, USA. Molecular Engineering & Sciences Institute, Univer
Author Info: (1) Department of Bioengineering, University of Washington, USA. (2) Department of Bioengineering, University of Washington, USA. Molecular Engineering & Sciences Institute, University of Washington, USA.
Citation: BME Front 2024 5:0038 Epub03/21/2024
Link to PUBMED: http://www.ncbi.nlm.nih.gov/pubmed/38515636